205393-21-1,
Bortezomib intermediates II,
(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide hydrochloride,
(S)-2-amino-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-3-phenylpropanamide hydrochloride,
AK162832,
Bortezomib Intermediate 2,
MFCD18252917,
AKOS024462775,
DS-7916,
AC-24854,
393A211,
Benzenepropanamide, alpha-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-, hydrochloride (1:1), (alphaS)-,
N-{(1R)-3-Methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]dec-4-yl]butyl}-L-phenylalaninamide hydrochloride (1:1),
BYRWVECJDRGBAH-UMPWXGAWSA-N,